Drug developer Vical Inc. said Thursday a drug aimed at preventing a potentially fatal virus in stem cell transplant patients showed positive results in a midstage study.
The company said the TransVax cytomegalovirus vaccine demonstrated sustained increases in cellular and antibody immune response in the final 12-month followup to an ongoing trial midstage study.
Cytomegalovirus can cause respiratory illness and is suppressed by the immune system in most people. But it can cause transplant rejection if it flares up when a transplant recipient's immune system is suppressed during recovery.
Shares rose 21 cents, or 5.6 percent, to $3.74 in premarket trading.